The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially

in the low- and middle-income countries. Currently, drugs administered for infantile spasm are intended for the treatment of seizures. However, they fail to check the progression of the disease. In addition, any neuronal damage incurred cannot be reversed. The treatment-refractory disease also poses a significant threat to life expectancy and quality of life for patients. Furthermore, these drugs are also associated with side effects such as weight gain, blurred vision, and dizziness. These drugs are also known to increase suicide risks.

PART 01: Executive summary 6

PART 02: Scope of the report 17

Market overview 17

Top-vendor offerings 18

PART 03: Market research methodology 19

Research methodology 19

Economic indicators 19

PART 04: Introduction 20

Key market highlights 20

PART 05: Infantile spasm: Overview 21

PART 06: Market landscape 22

Global infantile spasms therapeutics market 22

Five forces analysis 28

PART 07: Market segmentation by dosage form 29

Solid 29

Liquid 29

PART 08: Market segmentation by ROA 30

Oral 30

Parenteral 30

PART 09: Geographical segmentation 32

Infantile spasms therapeutics market in Americas 33

Infantile spasms therapeutics market in EMEA 40

Infantile spasms therapeutics market in APAC 44

PART 10: Market drivers 48

Major drugs launch expected in 2017-2021 48

Growing scientific advancements in diagnostics 51

Special regulatory designations 52

PART 11: Impact of drivers 53

PART 12: Market challenges 54

Growing usage of seizure management devices, a threat

to drug therapies 54

Limited patient population 54

Moderate pipeline 55

PART 13: Impact of drivers and challenges 57

PART 14: Market trends 58

Development of devices and smartphone apps to detect

seizures and track medications 58

Alternate drugs fill the gap 59

Reformulation of marketed drugs 59

PART 15: Vendor landscape 60

Competitive scenario 60

Other prominent vendors 62

PART 16: Key vendor analysis 63

H. Lundbeck 63

Mallinckrodt Pharmaceuticals 65

INSYS Therapeutics 68

PART 17: Appendix 71

List of abbreviations 71

PART 18: Explore Technavio 72